Study Demonstrates Efficacy of Pitavastatin in Elderl...(in various manufacturing and trading act...),Health

Date:6/16/2009

in various manufacturing and trading activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and various consumer products. Kowa's pharmaceutical division is focused on cardiovascular therapeutics, with fiscal year 2008 sales of the company's flagship product, LIVALO(R) (pitavastatin) totaling $340 million in Japan.

Kowa Pharmaceuticals America, Inc. is a specialty pharmaceutical company focused primarily in the area of cardiology. The company, started in 2001 as ProEthic Pharmaceuticals, Inc., was acquired by Kowa Company, Ltd. in September of 2008. A privately held company, KPA focuses its efforts on the acquisition, development, licensing and marketing of pharmaceutical products. Its lead product, LIPOFEN(R) (fenofibrate capsules), is indicated as adjunctive therapy to diet to reduce elevated triglycerides and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

For more information about KPA, please visit www.kowapharma.com.

'/>"/>

SOURCE Kowa Company Ltd. and Kowa Pharmaceuticals America, Inc. Copyright©2009 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3
Related medicine technology :

1. Study Suggests Vitamin D Screening and Appropriate Supplementation Indicated for All Cancer Patients
2. UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients
3. Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior to Laser for Varicose Vein Treatment
4. Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
5. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
6. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
7. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
8. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
9. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
10. Study Shows GSKs Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
11. New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients Blood Sugar